Antidepressant utilization, adherence, and health care spending in the United States: The case of MDD patients 2000-2007

Health Outcomes Research in Medicine

Volumn 2, Issue 2, 2011, Pages

  Lin, Hsien Chang ^a   Erickson, Steven R ^b   Balkrishnan, Rajesh ^b  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Antidepressant utilization; Drug expenditure; Health expenditure; Major depressive disorder (MDD); Medication adherence; Patient factor

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; DRUG UTILIZATION; ETHNICITY; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

EID: 84860393629     PISSN: None     EISSN: 18771319     Source Type: Journal    
DOI: 10.1016/j.ehrm.2011.06.003     Document Type: Article

References (37)

1. Compton WM, Conway KP, Stinson FS, et al. Changes in the prevalence of major depression and comorbid substance use disorders in the United States between 1991-1992 and 2001-2002. Am J Psychiatry. 2006;163: 2141-2147. (Pubitemid 46114235)
2. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62: 593-602. (Pubitemid 40973434)
3. The World Health Organization (WHO). The World Health Report 2004: Changing History. Geneva, Switzerland: WHO; 2004.
4. Simon GE, Von Korff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA. 1996;275:1897-1902. (Pubitemid 26196450)
5. Nelson JC. Safety and tolerability of the new antidepressants. J Clin Psychiatry. 1997;58(Suppl 6):26-31.
6. Mason J, Freemantle N, Eccles M. Fatal toxicity associated with antidepressant use in primary care. Br J Gen Pract. 2000;50:366-370. (Pubitemid 30245614)
7. Williams JW Jr, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med. 2000;132:743-756. (Pubitemid 30244176)
8. Frank L, Revicki DA, Sorensen SV, et al. The economics of selective serotonin reuptake inhibitors in depression: a critical review. CNS Drugs. 2001; 15:59-83. (Pubitemid 32128491)
9. Zuvekas SH. Prescription drugs and the changing patterns of treatment for mental disorders, 1996-2001. Health Aff (Millwood). 2005;24: 195-205. (Pubitemid 40169788)
10. Katon W, Sullivan MD. Depression and chronic medical illness. J Clin Psychiatry. 1990;51(Suppl):3-11. discussion 12-4. (Pubitemid 20212857)
11. Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA. 1998; 280:1665-1672. (Pubitemid 28532989)
12. Lewinsohn PM, Zeiss AM, Duncan EM. Probability of relapse after recovery from an episode of depression. J Abnorm Psychol. 1989;98: 107-116. (Pubitemid 19134398)
13. Depression Guideline Panel. Clinical Practice Guideline, Depression in Primary Care. Rockville, MD: US Department of Health and Human Services, Public Health Service Agency for Health Care Policy and Research; 1993.
14. Ramana R, Paykel ES, Cooper Z, et al. Remission and relapse in major depression: a two-year prospective follow-up study. Psychol Med. 1995;25: 1161-1170.
15. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000; 157:1-45.
16. Katon W, Cantrell CR, Sokol MC, et al. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Arch Intern Med. 2005;165:2497-2503. (Pubitemid 41720012)
17. Olfson M, Marcus SC, Tedeschi M, et al. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry. 2006;163:101-108. (Pubitemid 43050110)
18. Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003;25:2958-2971. (Pubitemid 37510603)
19. Vik SA, Maxwell CJ, Hogan DB. Measurement, correlates, and health outcomes of medication adherence among seniors. Ann Pharmacother. 2004;38:303-312. (Pubitemid 38112246)
20. Piette JD, Wagner TH, Potter MB, et al. Health insurance status, costrelated medication underuse, and outcomes among diabetes patients in three systems of care. Med Care. 2004;42:102-109.
21. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther. 1998;20:764-771. (Pubitemid 28421497)
22. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol. 2007;102:1417-1426. (Pubitemid 46976288)
23. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005; 43:521-530. (Pubitemid 40847288)
24. Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36:1-10.
25. American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
26. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356: 1711-1722. (Pubitemid 46658703)
27. Hirschfeld RM. Guideline Watch: Practice Guideline for the Treatment of Patients with Bipolar Disorder. Arlington, VA: American Psychiatric Association; 2005.
28. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997; 50:105-116. (Pubitemid 27089212)
29. Coombs JH, Cornish L, Hiller P, et al. Compliance and refill pattern behavior with HMG-CoA reductase inhibitors after acute myocardial infarction. Manag Care Interface. 2002;15:54-58, 60.
30. Epocrates Online [Internet]. Available from http://online.epocrates.com.
31. Lee ES, Forthofer RN, Lorimor RJ. Analysis of complex sample survey data: problems and strategies. Sociol Methods Res. 1986;15:69-100.
32. Wells K. Ethnic disparities in unmet need for alcoholism, drug abuse, and mental health care. Am J Psychiatry. 2001;158:2027-2032. (Pubitemid 33104109)
33. Harman JS. Disparities in the adequacy of depression treatment in the United States. Psychiatr Serv. 2004;55:1379-1385. (Pubitemid 39577973)
34. Miranda J, Cooper LA. Disparities in care for depression among primary care patients. J Gen Intern Med. 2004;19:120-126. (Pubitemid 38368460)
35. Chen J. Racial and ethnic disparities in antidepressant drug use. J Ment Health Policy Econ. 2008;11:155-165.
36. Zygmunt A, Olfson M, Boyer CA, et al. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry. 2002;159:1653-1664.
37. Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry. 2002;159:103-108. (Pubitemid 41070734)